Open AccessClinical Actionability Enhanced through Deep Targeted Sequencing of Solid Tumors
Author(s) -
Ken Chen,
Funda MericBernstam,
Hao Zhao,
Qingxiu Zhang,
Nader Ezzeddine,
Lin-Ya Tang,
Yuan Qi,
Yong Mao,
Tenghui Chen,
Zechen Chong,
Wanding Zhou,
Xiaofeng Zheng,
Amber M. Johnson,
Kenneth Aldape,
Mark J. Routbort,
Rajyalakshmi Luthra,
Scott Kopetz,
Michael A. Davies,
John de Groot,
Stacy Moulder,
Vinod Ravi,
Carol Farhangfar,
Kenna M. Shaw,
John Mendelsohn,
Gordon B. Mills,
Agda Karina Eterovic
Publication year - 2015
Publication title -
clinical chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.705
H-Index - 218
eISSN - 1530-8561
pISSN - 0009-9147
DOI - 10.1373/clinchem.2014.231100
Subject(s) - indel , nonsynonymous substitution , deep sequencing , dna sequencing , biology , germline mutation , genetics , computational biology , gene , mutation , genome , genotype , single nucleotide polymorphism
Further advances of targeted cancer therapy require comprehensive in-depth profiling of somatic mutations that are present in subpopulations of tumor cells in a clinical tumor sample. However, it is unclear to what extent such intratumor heterogeneity is present and whether it may affect clinical decision-making. To study this question, we established a deep targeted sequencing platform to identify potentially actionable DNA alterations in tumor samples.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom